Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 4Q Financial Reports: Genentech | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

4Q Financial Reports: Genentech

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genentech

4Q Revenues: $1.9 billion (+44%)

4Q Earnings: $339.2 million (+64%)

FY Revenues: $6.6 billion (+44%)

FY Earnings: $1.3 billion (+63%)

Comments: Product sales were up 45% in 2005 to $5.2 million. Sales for the quarter increased 47% to $1.5 million. Rituxan sales were up 16% for the year to $1.8 million and sales for the quarter were up 13% to $484.4 million. Sales of Avastin increased 108% for the year to $1.1 billion and sales increased 89% to $359.1 million for the quarter. Herceptin sales increased 56% for the year to $747.2 million and 98% to $250.1 million for the quarter. Tarceva sales were $274.9 million for the year, compared to $13.3 million in 2004. Xolair sales increased 71% to $320.6 million for the year and increased 55% to $93.3 million for the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters